Autres langues Guard Therapeutics International AB

Actions

GUARD

SE0021181559

Marché Fermé - Nasdaq Stockholm Autres places de cotation 17:24:44 03/05/2024			Varia. 5j.	Varia. 1 janv.
30 ^SEK	0,00 %		+0,67 %	-16,20 %

21/02	Guard Therapeutics International AB (publ) annonce ses résultats pour le quatrième trimestre clos le 31 décembre 2023	CI
21/02	Guard Therapeutics International AB (publ) annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Guard Therapeutics receives its first regulatory approval for the phase 2b study POINTER	15/04
Guard Therapeutics Receives First Regulatory Approval for the Phase 2b Study POINTER	15/04
Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/02
Guard Therapeutics International AB Reports Earnings Results for the Full Year Ended December 31, 2023	21/02
Guard Therapeutics presented development strategy and new preclinical results at R&D Update	31/01
Guard Therapeutics Presents Development Strategy and New Preclinical Results at R&D Update	31/01
Invitation to Guard Therapeutics’ R&D Update on January 30	18/01
US FDA Gives Positive Feedback on Guard Therapeutics’ RMC-035 Development Plan; Stock Plunges	15/01
FDA provides positive feedback to Guard Therapeutics regarding the continued development plan for RMC-035	15/01
Guard Therapeutics International AB Announces Fda Provides Positive Feedback to Guard Therapeutics Regarding the Continued Development Plan for RMC-035	15/01
Guard Therapeutics presents the Nomination Committee for 2024	07/12
Guard Therapeutics International AB Appoints Nomination Committee for 2024	07/12
Guard Therapeutics International AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Guard Therapeutics presents late breaking clinical trial abstract at ASN Kidney Week 2023	23/10/23
Guard Therapeutics provides more information on the development strategy for RMC-035	28/09/23
Guard Therapeutics International AB Provides More Information on the Development Strategy for RMC-035	28/09/23
Guard Therapeutics reports robust efficacy of RMC-035 in Phase 2 (AKITA) and advances clinical development program	19/09/23
Guard Therapeutics Reports Robust Efficacy of RMC-035 in Phase 2 and Advances Clinical Development Program	19/09/23
Guard Therapeutics International AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/08/23
Last patient visit completed in Guard Therapeutics' clinical Phase 2 study AKITA	14/07/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Guard Therapeutics International AB

Actions

GUARD

SE0021181559

Autres langues

Filtres